In terms of immune checkpoints, including PD-1 and CTLA4, we discovered that TIDE scores were more accumulated in the high-risk cohort (Figure 8A), which implied these patients hold potential immune dysfunction in tumors and could hardlybenefit from immunotherapy. Here, CTLA4 is linked to immune system disorder.